AOP Orphan Pharmaceuticals announces five-year results on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) Annual Meeting 20207. 12. 2020
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alpha-2b)27. 10. 2020
Rare disease pioneer AOP Orphan takes over two health care companies, strengthening its position in Europe as well as Vienna as a research- and business hub.12. 10. 2020
"AOP Orphan is the European pioneer in Orphan Diseases unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases."
"AOP Orphan having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."
"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."